Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment

Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment

Background The combination of atezolizumab and bevacizumab (Atezo-Bev) has become the standard first-line therapy for patients with advanced hepatocellular carcinoma (HCC), but the prognosis and treatment pattern after its treatment failure are unclear. Methods We reviewed the medical records of pat...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology international 2022-10, Vol.16 (5), p.1199-1207
Main Authors: Chen, Ching-Tso, Feng, Yin-Hsun, Yen, Chia-Jui, Chen, San-Chi, Lin, Yun-Tzu, Lu, Li-Chun, Hsu, Chih-Hung, Cheng, Ann-Lii, Shao, Yu-Yun
Format: Article
Language:eng
Subjects:
Bevacizumab
Colorectal Surgery
Failure
Health care facilities
Hepatocellular carcinoma
Hepatology
Liver
Liver cancer
Liver diseases
Medical prognosis
Medical records
Medicine
Medicine & Public Health
Multivariate analysis
Original Article
Patients
Prognosis
Surgery
Therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The combination of atezolizumab and bevacizumab (Atezo-Bev) has become the standard first-line therapy for patients with advanced hepatocellular carcinoma (HCC), but the prognosis and treatment pattern after its treatment failure are unclear. Methods We reviewed the medical records of patients who failed first-line Atezo-Bev treatment for advanced HCC from January 2018 to May 2021 in four Taiwan medical centers. Post-first-line survival (PFLS) was defined as the date from the failure of Atezo-Bev treatment to the date of death or last follow-up. Results A total of 41 patients were included in the study. All patients had Child–Pugh A liver reserve before the initiation of Atezo-Bev treatment, but the liver reserve of 6 (15%) and 7 (17%) patients deteriorated to Child–Pugh B and C, respectively, after treatment failure. The median PFLS was 5.9 months. PFLS significantly differed among patients with various liver reserves after the failure of Atezo-Bev treatment (median 9.6 vs 3.8 vs 1.2 months, for Child–Pugh A, B, and C; p  
ISSN:1936-0533
1936-0541